Extended-release tacrolimus to improve thinking and memory in older kidney transplant recipients
Official title: Neurocognitive Function Changes With Once-Daily Extended-Release Tacrolimus (Envarsus XR) Conversion Compared to Twice-Daily Immediate Release Tacrolimus Maintenance Among Older Kidney Transplant Recipients
Run by Massachusetts General Hospital · NCT06751992 · Data updated 2026-11-12
This will try switching older kidney transplant recipients from immediate-release tacrolimus to an extended-release formulation to see if it improves thinking, memory, or other cognitive symptoms.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 65 Years and up |
| Sex | All |
| Enrollment | 92 (estimated) |
| Sponsor | Massachusetts General Hospital Academic / other |
| Locations | 1 site (Boston, Massachusetts) |
| Status | Recruiting |
| Started | March 17, 2026 |
| Main results expected | May 1, 2027 |
| Study ends | October 1, 2027 |
| Registry record updated | May 28, 2026 |
| Trial ID | NCT06751992 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are older kidney transplant recipients at least one year after transplant who are on stable immediate-release tacrolimus with therapeutic troughs, have stable kidney function, receive care at MGH, and speak English or Spanish.
✕Probably not a fit
Patients with moderate-to-severe dementia, Parkinson's disease, recent rejection, dual organ transplants, severe kidney or liver dysfunction, active cancer, uncontrolled psychiatric illness, pregnancy, or other listed exclusions are unlikely to benefit or are not eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized, controlled, single-center trial at Massachusetts General Hospital compares continuing immediate-release tacrolimus with conversion to an extended-release formulation (Envarsus XR) in older kidney transplant recipients who are at least one year post-transplant and have stable tacrolimus levels. Participants are randomized to either maintain their current immediate-release regimen or be converted to the extended-release product, with neurocognitive testing performed at baseline and follow-up to measure changes in cognition and related symptoms. The trial enrolls patients who receive routine follow-up at the MGH transplant clinic and who speak English or Spanish. Safety monitoring includes routine graft function and tacrolimus trough level checks during the maintenance period.
Why it matters
Potential benefit: If successful, switching to extended-release tacrolimus could reduce neurotoxic side effects and lead to better cognitive function and quality of life for older transplant recipients.
How similar studies have gone: Some prior work indicates extended-release tacrolimus can lower peak-related side effects such as tremor, but direct evidence showing cognitive improvement in older kidney transplant recipients is limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Able to give informed consent for participation in the study * Patients who have regular outpatient follow-up at the Massachusetts General Hospital (MGH) transplant center * ≥1 year since the latest kidney transplantation * On IR tacrolimus as maintenance therapy * At a stable therapeutic tacrolimus level (5-10 ng/ml) over the last ≥3 months * Stable kidney function \[\<20% variability between the last two estimated glomerular filtration rate (eGFR)\] * Utilizing English or Spanish as the primary language Exclusion Criteria: * Dual organ transplantation * Rejection within the last three months * History of moderate to severe dementia (defined by Dementia Severity Rating Scale ≥19) * History of Parkinson's disease * Decompensated liver disease * Active cancer * Uncontrolled depression or anxiety * Blindness * Deafness * Intellectual disabilities * Pregnancy * eGFR \<15 mL/min/1.73 m2 at the time of enrollment * Total bilirubin \>3.0 mg/dL
Where it's running
-
MGH Kidney Transplant Clinic
Boston, Massachusetts, United States Recruiting
Study contacts
- Principal investigator: Leonardo V. Riella, MD, PhD — Massachusetts General Hospital
- Study coordinator: Leonardo V. Riella, MD, PhD
- Email: lriella@mgh.harvard.edu
- Phone: 6177240345
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Fall Prevention Pathways: A digital program to help older adults reduce fall risk
A digital, remotely monitored 8-week program is being tested to see if it can reduce fall risk in community-dwelling adults aged 65–85 who are at low to moderate risk.
-
Mental effort with light resistance training for older adults
This study tests whether adding a mental effort cue to light resistance training helps older adults build more strength and improve neuromuscular function than light training alone.
-
Combined NMES and Low-Intensity Resistance Training in Older Adults
This study tests whether pairing electrical stimulation with light resistance training helps older adults gain muscle strength and endurance.
-
Inspiring Seniors to Exercise More with Personalized Music
This study tests whether personalized tempo-matched music playlists help sedentary adults age 65 and older exercise more and feel better about physical activity.
-
Diode laser–assisted gum treatment for people with kidney transplants
This project will test whether adding a diode laser to standard deep dental cleaning (scaling and root planing) helps people with periodontitis who have had a kidney transplant.
-
Home safety modifications to prevent falls in older adults in Guangzhou
This project will try simple home changes like anti-slip mats, better lighting, and minor hazard fixes to see if they reduce falls among community-dwelling people aged 60–80 in Guangzhou over 12 months.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.